Assembly Biosciences (ASMB) Short term Debt (2010)

Assembly Biosciences (ASMB) recorded quarterly Short term Debt of $419380.0 in Q4 2010.

Assembly Biosciences (ASMB) Short term Debt (2010) Analysis & Trends

Assembly Biosciences' Short term Debt history runs 1 years deep, the most recent figure standing at $419380.0 for Q4 2010.

In Q4 2010, Short term Debt changed N/A year-over-year to $419380.0; the TTM figure through Dec 2010 stood at $419380.0 (changed N/A YoY), while the FY2010 annual figure was $419380.0, changed N/A from the prior year.
Short term Debt was $419380.0 for Q4 2010 at Assembly Biosciences.
In the past five years, Short term Debt ranged from a high of $419380.0 in Q4 2010 to a low of $419380.0 in Q4 2010.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Assembly Biosciences	418.96 Mn	192.36 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2010	419,380.00